Chlamydia Vaccine Shows Promise in Early Trial

DLHA Staff Writer

THURSDAY, April 18, 2024 -- A chlamydia vaccine has shown promise in the United States in an early trial, as it triggered immune responses, raising hopes that one day it might help curb the spread of the sexually transmitted infection (STI), worldwide.

There is currently no vaccine for chlamydia, which is a common bacterial STI globally as well as in most countries of Africa. Other common bacterial STI in the Africa include gonorrhea and syphilis.

In the new trial results, published April 11 in the journal Lancet Infectious Diseases, the vaccine was found to be safe and it also prompted an antibody response.

Chlamydia is a common cause of infertility in women, because it causes pelvic inflammatory disease, making it harder to get pregnant.

The bacteria can also cause an eye infection that leads to vision loss in 1.9 million people worldwide.

The hope generated by the research is that the vaccine against chlamydia could one day prevent both infections in the reproductive system and the eyes, said study author Jes Dietrich, a senior scientist at Statens Serum Institut in Denmark.

There are a handful of vaccines that can prevent other sexually transmitted infections: the HPV vaccine, the hepatitis B vaccine and the mpox vaccine.

Source

Lancet Infectious Diseases, April 11, 2024 Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00147-6/abstract

Related:

Pelvic Inflammatory Disease in Africa: Causes and Symptoms

Pelvic Inflammatory Disease in Africa: Diagnosis and Treatment

Published: April 18, 2024

© 2024. Datelinehealth Africa Inc. All rights reserved.

Permission is given to copy, use and share content for non-commercial purposes without alteration or modification and subject to attribution as to source.